Solengepras, an experimental once-daily pill for Parkinson’s disease, significantly reduces the time patients spend with re-emerging symptoms, known as off episodes. New Phase 2 data suggest the treatment reduces both the frequency and length of these difficult periods when standard medication wears off. The trial (…
News
Dysfunctional nerve cells in the brain’s motor command center may be driving the rigid brain wave patterns associated with Parkinson’s disease, a new supercomputer simulation reveals. The study suggests that specific neurons, known as PT5B, significantly alter brain wave frequency during movement. These neurons are responsible for…
People with Parkinson’s disease exhibit an interplay between the loss of dopamine-producing neurons and overall nerve cell connections, or synapses, in two key brain regions that is distinct from that seen in individuals without the disease, according to a recent study. Researchers demonstrated that in Parkinson’s,…
The Parkinson’s Foundation has published a new journal article outlining a practical pathway for making hospital care more age friendly for older people living with Parkinson’s disease. The work aims to translate — into everyday practices — the Age-Friendly Hospital Measure set forth by the Centers for Medicare…
Aerobic exercise may help alleviate motor symptoms and reduce anxiety in early Parkinson’s disease, but there’s a chance higher-intensity workouts may do more harm than good, a mouse study suggested. The results show that “a broad range of symptoms should be assessed in clinical studies with different exercise…
An analysis of electronic health records from 11.3 million U.S. veterans suggests obstructive sleep apnea nearly doubles the risk of developing Parkinson’s disease. But early treatment with continuous positive airway pressure (CPAP), the standard therapy for the condition, may cut that risk by about 30%, the study found, “If…
Cure Parkinson’s and France Parkinson have joined forces to launch a new international initiative, the Global Alliance for Parkinson’s Platforms (GAPP). This alliance brings together leaders from around the world to unite their efforts in running platform trials. This approach simultaneously tests potential disease-modifying treatments for Parkinson’s…
A wrist-worn device may provide a clearer and more consistent picture of tremor in Parkinson’s disease than what can be seen during a single clinic visit or recalled from memory alone, a study has found, adding to evidence that wearable sensors can help track motor symptoms in daily…
Early treatment with the investigational small molecule golexanolone improved motor and cognitive function and eased signs of fatigue, anxiety, and depression in a rat model of Parkinson’s disease. The Umecrine Cognition treatment also reduced neuroinflammation and improved dopamine levels, a study found. Golexanolone “could be considered for clinical evaluation…
The Michael J. Fox Foundation (MJFF) has awarded a $2 million grant to Enigma Biomedical USA for the development and first preclinical testing of a new positron emission tomography (PET) tracer that targets harmful clumps of the protein alpha-synuclein, a hallmark and suspected driver of Parkinson’s disease. The…
Recent Posts
- Cell therapy eases Parkinson’s motor symptoms in early trial
- A sticky reminder about the dangers of losing your sense of smell
- New funding to support Serina’s SER-252 trial in advanced Parkinson’s
- Pirepemat shows promise in trial for reducing risk of falls in Parkinson’s
- When it comes to Parkinson’s, hope is not a plan, but urgent action is